In last trading session, C4 Therapeutics Inc (NASDAQ:CCCC) saw 0.45 million shares changing hands with its beta currently measuring 2.96. Company’s recent per share price level of $3.59 trading at -$0.04 or -1.10% at ring of the bell on the day assigns it a market valuation of $253.42M. That closing price of CCCC’s stock is at a discount of -230.92% from its 52-week high price of $11.88 and is indicating a premium of 5.85% from its 52-week low price of $3.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.99 million shares which gives us an average trading volume of 1.66 million if we extend that period to 3-months.

For C4 Therapeutics Inc (CCCC), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.44 in the current quarter.

C4 Therapeutics Inc (NASDAQ:CCCC) trade information

Upright in the red during last session for losing -1.10%, in the last five days CCCC remained trading in the red while hitting it’s week-highest on Thursday, 01/23/25 when the stock touched $3.59 price level, adding 5.28% to its value on the day. C4 Therapeutics Inc’s shares saw a change of -0.28% in year-to-date performance and have moved -3.23% in past 5-day. C4 Therapeutics Inc (NASDAQ:CCCC) showed a performance of -10.25% in past 30-days. Number of shares sold short was 9.28 million shares which calculate 4.72 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 16 to the stock, which implies a rise of 77.56% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 20. It follows that stock’s current price would drop -234.26% in reaching the projected high whereas dropping to the targeted low would mean a loss of -234.26% for stock’s current value.

C4 Therapeutics Inc (CCCC) estimates and forecasts

Statistics highlight that C4 Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -45.11% of value to its shares in past 6 months, showing an annual growth rate of 43.07% while that of industry is 16.20. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 72.57% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.33M for the same. And 3 analysts are in estimates of company making revenue of 3.33M in the next quarter. Company posted 3.26M and 3.04M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -36.05% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 42.65% while estimates for its earnings growth in next 5 years are of 12.00%.

C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders

Insiders are in possession of 11.42% of company’s total shares while institution are holding 91.52 percent of that, with stock having share float percentage of 103.32%. Investors also watch the number of corporate investors in a company very closely, which is 91.52% institutions for C4 Therapeutics Inc that are currently holding shares of the company. LYNX1 CAPITAL MANAGEMENT LP is the top institutional holder at CCCC for having 6.88 million shares of worth $31.79 million. And as of 2024-06-30, it was holding 9.9993 of the company’s outstanding shares.

The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 4.88 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0891 of outstanding shares, having a total worth of $22.54 million.

On the other hand, Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 2.61 shares of worth $9.37 million or 3.70% of the total outstanding shares. The later fund manager was in possession of 2.14 shares on Sep 30, 2024 , making its stake of worth around $7.67 million in the company or a holder of 3.03% of company’s stock.